Search research articles
Contact Us
Filters
Showing results (181-190 of 587) with videos related to
Page
of 59
Sort By:
Journal of Neural Transmission (Vienna, Austria : 1996)
|
August 12, 1999
Parkinson's disease: a major hypokinetic basal ganglia disorder
J Sian, M Gerlach, M B Youdim, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)
|
September 27, 2005
Central administration of alloxan impairs glucose tolerance in rats
M Salkovic-Petrisic, Z Lackovic, S Hoyer, et al.
British Journal of Pharmacology
|
November 1, 1976
L-dopa and (-)-deprenil in the treatment of Parkinson's disease: a long-term study [proceedings]
L Ambrozi, W Birkmayer, P Riederer, et al.
Modern Problems of Pharmacopsychiatry
|
January 1, 1983
(-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease
W Birkmayer, J Knoll, P Riederer, et al.
Metabolic Brain Disease
|
March 1, 1989
Biochemical events in spontaneous seizures in the Mongolian gerbil
R Wolf-Dieter, G Heuschneider, G Sperk, et al.
Advances in Experimental Medicine and Biology
|
January 5, 2002
A sensitive procedure for the determination of protein bound 3,4-dihydroxyphenyl-alanine as a marker for posttranslational protein hydroxylation in human frontal cortex, liver, and red blood cells
R Harth, M Gerlach, P Riederer, et al.
Biogerontology
|
November 16, 2001
AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs?
S Dukic-Stefanovic, R Schinzel, P Riederer, et al.
Journal of Neural Transmission
|
January 1, 1975
The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil
W Birkmayer, P Riederer, M B Youdim, et al.
Journal of Neural Transmission. Supplementum
|
January 1, 1995
Interaction of neuroprotective substances with human brain superoxide dismutase. An in vitro study
W Gsell, N Reichert, M B Youdim, et al.
Advances in Neurology
|
July 20, 1999
Nitric oxide in the pathogenesis of Parkinson's disease
M Gerlach, D Blum-Degen, J Lan, et al.
Page
of 59
Search research articles
Search
Showing results (181-190 of 587) with videos related to
Sort By:
Page
of 59
Journal of Neural Transmission (Vienna, Austria : 1996)
|
August 12, 1999
Parkinson's disease: a major hypokinetic basal ganglia disorder
J Sian, M Gerlach, M B Youdim, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)
|
September 27, 2005
Central administration of alloxan impairs glucose tolerance in rats
M Salkovic-Petrisic, Z Lackovic, S Hoyer, et al.
British Journal of Pharmacology
|
November 1, 1976
L-dopa and (-)-deprenil in the treatment of Parkinson's disease: a long-term study [proceedings]
L Ambrozi, W Birkmayer, P Riederer, et al.
Modern Problems of Pharmacopsychiatry
|
January 1, 1983
(-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease
W Birkmayer, J Knoll, P Riederer, et al.
Metabolic Brain Disease
|
March 1, 1989
Biochemical events in spontaneous seizures in the Mongolian gerbil
R Wolf-Dieter, G Heuschneider, G Sperk, et al.
Advances in Experimental Medicine and Biology
|
January 5, 2002
A sensitive procedure for the determination of protein bound 3,4-dihydroxyphenyl-alanine as a marker for posttranslational protein hydroxylation in human frontal cortex, liver, and red blood cells
R Harth, M Gerlach, P Riederer, et al.
Biogerontology
|
November 16, 2001
AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs?
S Dukic-Stefanovic, R Schinzel, P Riederer, et al.
Journal of Neural Transmission
|
January 1, 1975
The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil
W Birkmayer, P Riederer, M B Youdim, et al.
Journal of Neural Transmission. Supplementum
|
January 1, 1995
Interaction of neuroprotective substances with human brain superoxide dismutase. An in vitro study
W Gsell, N Reichert, M B Youdim, et al.
Advances in Neurology
|
July 20, 1999
Nitric oxide in the pathogenesis of Parkinson's disease
M Gerlach, D Blum-Degen, J Lan, et al.
Page
of 59